Clinical trial · people
MK-677: about 50% more stage IV sleep in young adults on 25 mg
Checked against the paper Clinical trialPublished by PepVault
The takeaway
An early, small trial in healthy people linked short-term MK-677 use to more deep sleep and REM sleep, with no data on longer use.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 1997
- Journal
- Neuroendocrinology
What they tested
The team tested whether taking oral MK-677 for one to two weeks changes sleep quality in healthy young and older adults.
How the study was done
A double-blind, placebo-controlled crossover trial (each person tried every option, in random order) in a small group of healthy adults aged 18-30, who took 5 mg MK-677, 25 mg MK-677 and placebo, a dummy pill, at bedtime for 7 days each, with at least 14 days between periods. A second small group aged 65-71 took 2 mg and then 25 mg at bedtime for 14 days each, with a 14-day washout between, compared against sleep and hormone data taken on the 2 days before treatment and with no placebo period.

What they found
In the young adults, the 25 mg dose increased stage IV sleep, the deepest sleep stage, by about 50% and REM sleep, the dreaming stage, by more than 20% compared with placebo (p < 0.05). Sleep that strayed from normal patterns dropped from 42% on placebo to 8% on the 25 mg dose (p < 0.03). In the older adults, MK-677 treatment was linked to a nearly 50% increase in REM sleep (p < 0.05), a shorter REM latency, the time it takes to reach the first REM period (p < 0.02), and fewer departures from normal sleep (p < 0.02).
What it doesn’t show
Both groups were very small, the treatment periods lasted only 7 to 14 days, and only healthy people took part. The older group had no placebo period and got the doses in a fixed order, so their results are weaker evidence than the young group's.
The paper
Copinschi et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997.
The compound
More studies on MK-677
- MK-677 raised IGF-1 but not most function after hip fractureRandomized trial · people · 2011
- MK-677: fat-free mass rose 1.1 kg vs -0.5 kg on placebo at 1 yearRandomized trial · people · 2008
- MK-677 reversed diet-driven nitrogen loss in 8 healthy adultsRandomized trial · people · 1998
- Every study on MK-677
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.